JP2004143154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004143154A5 JP2004143154A5 JP2003336240A JP2003336240A JP2004143154A5 JP 2004143154 A5 JP2004143154 A5 JP 2004143154A5 JP 2003336240 A JP2003336240 A JP 2003336240A JP 2003336240 A JP2003336240 A JP 2003336240A JP 2004143154 A5 JP2004143154 A5 JP 2004143154A5
- Authority
- JP
- Japan
- Prior art keywords
- observed
- edema
- cedar pollen
- instilled
- scored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
試験例
試験方法:実施例1、2、3、4、7、8及び9の点眼剤と表2に示した比較例1〜4の点眼剤を検体として用いた。スギ花粉を用いて感作したモルモット30匹を、スギ花粉惹起30分後の目のアレルギー症状が均等になるように1群8〜13匹に群分けした。各検体をモルモットの両眼に10μL点眼し、5分後にスギ花粉0.5mg(生食懸濁液10μL)を両目に点眼した。非点眼群は、スギ花粉のみ点眼した。スギ花粉投与後30分後の角結膜の状態を肉眼的に観察した。なお、角結膜の状態の評価はDraize法に準じて、発赤を0〜2の3段階、浮腫を0〜4の5段階、分泌物を0〜3の4段階(トータルスコアー9)でスコアー化した。各状態の評価を下記に示す。このスコアーよりアレルギー症状の改善率(%)を下記式にて算出し、表3に示した。
改善率(%)=100−[(点眼群のトータルスコアーの平均値)/(非点眼群のトータルスコアーの平均値)×100]
発赤
0:充血が全く認められない
1:結膜の一部に充血が認められる
2:結膜全体に充血が認められる
浮腫
0:浮腫が全く認められない
1:結膜の一部に軽い浮腫を認める
2:結膜全体に浮腫が認められる
3:浮腫が角膜の一部を覆っている
4:浮腫が角膜の半分以上を覆っている
分泌物
0:分泌物を認めない
1:明らかな涙液様の分泌物が認められる
2:粘性のある分泌物が認められる
3:分泌物が膜状になり眼瞼を覆っている
Test Example Test method: The eye drops of Examples 1, 2, 3, 4 , 7 , 8, and 9 and the eye drops of Comparative Examples 1 to 4 shown in Table 2 were used as samples. Thirty guinea pigs sensitized with cedar pollen were divided into groups of 8 to 13 animals so that allergic symptoms of the eyes 30 minutes after the cedar pollen induction were uniform. 10 μL of each sample was instilled into both eyes of a guinea pig, and 5 minutes later, 0.5 mg of cedar pollen (10 μL of a saline solution) was instilled into both eyes. In the non-instilled group, only cedar pollen was instilled. The state of the keratoconjunctiva 30 minutes after administration of the cedar pollen was visually observed. The evaluation of the keratoconjunctival condition was scored according to the Draize method according to the Draize method, with redness scored in three stages of 0-2, edema scored in five stages of 0-4, and secretions scored in four stages of 0-3 (total score of 9). did. The evaluation of each state is shown below. From this score, the improvement rate (%) of allergic symptoms was calculated by the following formula, and shown in Table 3.
Improvement rate (%) = 100 − [(average value of total score of eye drop group) / (average value of total score of non-drop group) × 100]
Redness 0: No congestion is observed at all. 1: Hyperemia is observed at a part of conjunctiva. 2: Edema is observed at entire conjunctiva. 0: No edema is observed. 1: Light edema is observed at a part of conjunctiva. : Edema covers the entire conjunctiva 3: Edema covers part of the cornea 4: Secretion in which edema covers more than half of the cornea 0: No secretion is observed 1: Clear tear-like secretion Objects are observed 2: Viscous secretions are observed 3: Secretions are film-like and cover eyelids
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003336240A JP2004143154A (en) | 2002-10-01 | 2003-09-26 | Ophthalmic solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002288407 | 2002-10-01 | ||
JP2003336240A JP2004143154A (en) | 2002-10-01 | 2003-09-26 | Ophthalmic solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004143154A JP2004143154A (en) | 2004-05-20 |
JP2004143154A5 true JP2004143154A5 (en) | 2006-07-06 |
Family
ID=32473330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003336240A Pending JP2004143154A (en) | 2002-10-01 | 2003-09-26 | Ophthalmic solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2004143154A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012144570A (en) * | 2005-04-19 | 2012-08-02 | Daiichi Sankyo Healthcare Co Ltd | Medicinal preparation to be applied to local mucous membrane containing ketotifen fumarate |
JP5080745B2 (en) * | 2005-04-19 | 2012-11-21 | 第一三共ヘルスケア株式会社 | Pharmaceutical composition for topical mucosa containing ketotifen fumarate |
CN101528211B (en) * | 2006-08-28 | 2012-10-10 | 千寿制药株式会社 | Ophthalmic percutaneous absorption type preparation |
-
2003
- 2003-09-26 JP JP2003336240A patent/JP2004143154A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103269686B (en) | Contact lens ophthalmic composition | |
Ren et al. | Evaluation of three different methods to establish animal models of Acanthamoeba keratitis | |
CY1110758T1 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF A RING OF A EYE | |
AU2019212565B2 (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
CN105792848A (en) | Aqueous composition for ophthalmological use or otolaryngological use | |
Fogagnolo et al. | Tear film osmolarity, ocular surface disease and glaucoma: a review | |
CN1604784A (en) | Heparin-containing ophthalmic agent | |
JP2004143154A5 (en) | ||
JP5132015B2 (en) | Eye drop composition | |
JP2002020279A (en) | Eye lotion | |
CN1241912C (en) | Disulfide derivatives useful for treating allergic diseases | |
JP6449774B2 (en) | Ophthalmic composition for zwitterionic soft contact lenses | |
JP2017036255A (en) | Ophthalmic composition | |
JP2005247821A (en) | Ophthalmic composition for suppressing production of inflammatory cytokine | |
CN101347619A (en) | Medicament composition and use thereof in preparing medicament for treating inflammation of eye section | |
WO2006118170A1 (en) | Therapeutic agent for corneal disease | |
DE60124732T2 (en) | GATIFLOXACIN AS INHIBITOR OF CYTOKIN PRODUCTION | |
JP2019038783A (en) | Dry eye therapeutic agent | |
RU2003111602A (en) | METHOD FOR DIAGNOSTIC OF DEGREE OF EXPRESSION OF DISORDERS OF HIGHER BRAIN FUNCTIONS | |
WO2023280319A1 (en) | Application of loxoprofen sodium in preparation of drug for treating dry eye disease | |
Singh | Assessment of the cause of Conjunctivitis in Adolescent Population | |
JP6401699B2 (en) | Ophthalmic composition for zwitterionic soft contact lenses | |
JPWO2007023877A1 (en) | Treatment for corneal diseases | |
Maślińska et al. | The Risk of Infection in Dry Eye Syndrome Accompanying Primary Sjögren’s Syndrome | |
JP2004143154A (en) | Ophthalmic solution |